National Bank of Canada’s BioLineRX BLRX Stock Holding History

National Bank of Canada’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200	Closed	-$914	–	2877
2025 Q2	$914	Buy	+200	New	+$739	﹤0.01%	2715

Other funds holding BLRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

National Bank of Canada's BLRX Position: Q3 2025 in Review

National Bank of Canada sold out of BioLineRX (BLRX) in Q3 2025, closing a stake of 200 shares — an estimated $914 sold.

National Bank of Canada first reported a position in BLRX in Q2 2025 and held it in 1 quarter. The position peaked at $914 in Q2 2025. 14 funds tracked by Wall St. Rank hold BLRX as of Q3 2025.

National Bank of Canada reported no remaining BioLineRX position as of Q3 2025 after selling out during the quarter.
National Bank of Canada sold 200 BioLineRX shares in Q3 2025, an estimated $914.
National Bank of Canada first reported a position in BioLineRX in Q2 2025 and held it in 1 quarter.
National Bank of Canada's BioLineRX position peaked at $914 in Q2 2025.
14 funds tracked by Wall St. Rank held BioLineRX as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.